Genital Herpes Market

Market Overview:

The 7 major genital herpes markets are expected to exhibit a CAGR of 3.49% during 2024-2034.

The genital herpes market has been comprehensively analyzed in IMARC's new report titled "Genital Herpes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Genital herpes is a common sexually transmitted illness that is caused by the herpes simplex virus (HSV). It primarily affects the genital and anal regions of the body, but it can also occur on the skin around the buttocks and thighs. The primary mode of viral spread is through sexual activity with an infected individual or direct skin-to-skin contact with a diseased area. Some common symptoms of this ailment include itching, tingling, or burning sensations, painful sores or blisters in the genital or anal region, fever, headache, muscle aches, swollen lymph nodes, etc. The diagnosis of the illness is mainly based on the patient's medical history, clinical features, and physical examination. Additionally, blood workups are recommended to detect the presence of antibodies against HSV, indicating a past or current infection even when no active symptoms are present. The healthcare provider will perform a polymerase chain reaction (PCR) test to determine the genetic material (DNA) of the herpes virus in the patient's sample. Furthermore, a viral culture screening is also required to confirm the diagnosis and identify the subtypes of the virus. 

The increasing prevalence of unprotected sexual activities, including vaginal, anal, or oral sex, that can enhance the likelihood of viral transmission among individuals is primarily driving the genital herpes market. In addition to this, the rising cases of weakened immune systems, which impair the body's ability to recognize and attack the pathogen, allowing it to replicate and cause active infections, are creating a positive outlook for the market. Moreover, the widespread adoption of antiviral drugs, like acyclovir, valacyclovir, famciclovir, etc., to shorten the duration of outbreaks, alleviate symptoms, and reduce the risk of viral transmission is further bolstering the market growth. Apart from this, the inflating application of topical analgesics, since they can be applied directly to the sores or blisters, thereby accelerating the healing mechanism and improving overall well-being, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of nucleoside reverse transcriptase inhibitors, which prevent viral replication by interfering with the DNA synthesis process, is expected to drive the genital herpes market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the genital herpes market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for genital herpes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the genital herpes market in any manner.

Key Highlights:

• Globally, approximately 90% of people carry either herpes simplex virus 1 or herpes simplex virus 2, the two forms of herpes simplex viruses that cause genital herpes.
• Herpes simplex virus 1 is more frequent than herpes simplex virus 2, with the majority of infections occurring during childhood.
• Herpes simplex virus 2 causes more genital lesions, whereas herpes simplex virus 1 causes more oral lesions.
• Genital herpes affects an estimated 20 million people in the United States, with approximately 25% of them experiencing symptoms.
• It is estimated that one in eight people in the United States have genital herpes.

Drugs:

Zovirax (Acyclovir) oral formulations treat herpes simplex virus infections on the skin and mucosal membranes, including first and recurrent genital herpes. ZOVIRAX is the brand name for acyclovir, a synthetic nucleoside analogue that works against herpesviruses. ZOVIRAX capsules, tablets, and suspension are for oral administration.

BNT163 is a vaccine candidate being developed by BioNTech for genital herpes. The vaccine is the first candidate from BioNTech's infectious disease mRNA vaccine collaboration with the University of Pennsylvania to begin clinical trials, and it is currently in the phase 1 of development. BNT163 is an mRNA-based vaccine that encodes three herpes simplex virus 2 glycoproteins to assist prevent herpes simplex virus cellular entry and transmission while also opposing the immunosuppressive effects of herpes simplex virus.

HDIT101 is a humanized monoclonal antibody with a new mechanism of action designed to treat herpes simplex virus 1 and 2 infections. HDIT101, or MAb2c of murine origin, recognizes viral gB, a glycoprotein found on the surface of herpes simplex virus 1 and herpes simplex virus 2 virions, as well as on the surface of virus-infected cells, but does not bind to uninfected human cells or cells in which herpes simplex virus is inactive. By inhibiting gB on herpes simplex virus virions, HDIT101 can effectively neutralize their infectivity. By binding to gB on herpes simplex virus-infected cells, HDIT101 prevents cell-to-cell transmission, a critical method by which herpes simplex virus might escape humoral immune monitoring.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the genital herpes market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the genital herpes market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current genital herpes marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the genital herpes market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the genital herpes market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the genital herpes market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of genital herpes across the seven major markets?
• What is the number of prevalent cases (2018-2034) of genital herpes by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of genital herpes by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with genital herpes across the seven major markets?
• What is the size of the genital herpes patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of genital herpes?
• What will be the growth rate of patients across the seven major markets?
   

Genital Herpes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for genital herpes drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the genital herpes market?
• What are the key regulatory events related to the genital herpes market?
• What is the structure of clinical trial landscape by status related to the genital herpes market?
• What is the structure of clinical trial landscape by phase related to the genital herpes market?
• What is the structure of clinical trial landscape by route of administration related to the genital herpes market?